BR112015025255A2 - métodos e arranjos para uso no mesmo - Google Patents
métodos e arranjos para uso no mesmoInfo
- Publication number
- BR112015025255A2 BR112015025255A2 BR112015025255A BR112015025255A BR112015025255A2 BR 112015025255 A2 BR112015025255 A2 BR 112015025255A2 BR 112015025255 A BR112015025255 A BR 112015025255A BR 112015025255 A BR112015025255 A BR 112015025255A BR 112015025255 A2 BR112015025255 A2 BR 112015025255A2
- Authority
- BR
- Brazil
- Prior art keywords
- arrangements
- individual
- test sample
- methods
- expression
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000090 biomarker Substances 0.000 abstract 3
- 206010060862 Prostate cancer Diseases 0.000 abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/246—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1305940.7A GB201305940D0 (en) | 2013-04-02 | 2013-04-02 | Methods and arrays for use in the same |
| PCT/EP2014/056630 WO2014161910A2 (en) | 2013-04-02 | 2014-04-02 | Methods and arrays for use in the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015025255A2 true BR112015025255A2 (pt) | 2017-10-10 |
Family
ID=48445139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015025255A BR112015025255A2 (pt) | 2013-04-02 | 2014-04-02 | métodos e arranjos para uso no mesmo |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10048265B2 (enExample) |
| EP (2) | EP3557259A3 (enExample) |
| JP (1) | JP6674889B2 (enExample) |
| KR (1) | KR102208140B1 (enExample) |
| CN (1) | CN105283763B (enExample) |
| AU (1) | AU2014247083B2 (enExample) |
| BR (1) | BR112015025255A2 (enExample) |
| CA (1) | CA2908527A1 (enExample) |
| GB (1) | GB201305940D0 (enExample) |
| HK (1) | HK1221504A1 (enExample) |
| MX (1) | MX374601B (enExample) |
| WO (1) | WO2014161910A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11450121B2 (en) * | 2017-06-27 | 2022-09-20 | The Regents Of The University Of California | Label-free digital brightfield analysis of nucleic acid amplification |
| US20210318317A1 (en) * | 2018-10-04 | 2021-10-14 | Konica Minolta, Inc. | Method for acquiring auxiliary information |
| US20230333111A1 (en) * | 2018-10-05 | 2023-10-19 | Minomic International Ltd. | Biomarker combinations for determining aggressive prostate cancer |
| KR102543618B1 (ko) | 2021-05-27 | 2023-06-13 | 사회복지법인 삼성생명공익재단 | 전립선암의 엔잘루타미드 저항성 예측용 신규 바이오마커 및 이의 용도 |
| IT202200019581A1 (it) * | 2022-09-23 | 2024-03-23 | Diesse Diagnostica Senese S P A | Apparecchiatura per l’esecuzione di test immunometrici |
| US20250362293A1 (en) * | 2022-09-23 | 2025-11-27 | Diesse Diagnostica Senese S.P.A. | Apparatus for performing immunometric tests |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0039578B1 (en) | 1980-05-02 | 1985-04-10 | Edward P. Davis | Leg aid device |
| US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US5856090A (en) | 1994-09-09 | 1999-01-05 | The Scripps Research Institute | DNA-methylase linking reaction |
| GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
| US20060269971A1 (en) * | 2003-09-26 | 2006-11-30 | Mount Sinai Hospital | Methods for detecting prostate cancer |
| EP2016394A4 (en) * | 2006-04-04 | 2013-04-24 | Singulex Inc | METHOD AND COMPOSITIONS FOR HIGHLY SENSITIVE ANALYSIS OF MARKERS AND DETECTION OF MOLECULES |
| US20090017463A1 (en) * | 2007-07-10 | 2009-01-15 | Vanderbilt University | Methods for predicting prostate cancer recurrence |
| AU2008298560A1 (en) | 2007-09-14 | 2009-03-19 | Ventana Medical Systems, Inc. | Prostate cancer biomarkers |
| WO2011016031A2 (en) * | 2009-08-03 | 2011-02-10 | Yeda Research And Development Co. Ltd. | Urinary biomarkers for cancer diagnosis |
-
2013
- 2013-04-02 GB GBGB1305940.7A patent/GB201305940D0/en not_active Ceased
-
2014
- 2014-04-02 CA CA2908527A patent/CA2908527A1/en not_active Abandoned
- 2014-04-02 MX MX2015013993A patent/MX374601B/es active IP Right Grant
- 2014-04-02 EP EP19157572.9A patent/EP3557259A3/en not_active Withdrawn
- 2014-04-02 KR KR1020157031458A patent/KR102208140B1/ko not_active Expired - Fee Related
- 2014-04-02 CN CN201480030354.9A patent/CN105283763B/zh not_active Expired - Fee Related
- 2014-04-02 US US14/781,839 patent/US10048265B2/en active Active
- 2014-04-02 HK HK16109510.4A patent/HK1221504A1/zh unknown
- 2014-04-02 EP EP14717703.4A patent/EP2981827A2/en not_active Ceased
- 2014-04-02 JP JP2016505813A patent/JP6674889B2/ja not_active Expired - Fee Related
- 2014-04-02 BR BR112015025255A patent/BR112015025255A2/pt not_active IP Right Cessation
- 2014-04-02 AU AU2014247083A patent/AU2014247083B2/en not_active Ceased
- 2014-04-02 WO PCT/EP2014/056630 patent/WO2014161910A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| HK1221504A1 (zh) | 2017-06-02 |
| WO2014161910A3 (en) | 2014-12-31 |
| CN105283763A (zh) | 2016-01-27 |
| MX374601B (es) | 2025-03-06 |
| JP2016519767A (ja) | 2016-07-07 |
| AU2014247083A1 (en) | 2015-11-19 |
| WO2014161910A2 (en) | 2014-10-09 |
| US10048265B2 (en) | 2018-08-14 |
| EP3557259A3 (en) | 2020-01-22 |
| US20160041173A1 (en) | 2016-02-11 |
| JP6674889B2 (ja) | 2020-04-01 |
| KR102208140B1 (ko) | 2021-01-27 |
| EP3557259A2 (en) | 2019-10-23 |
| MX2015013993A (es) | 2016-07-07 |
| AU2014247083B2 (en) | 2020-03-26 |
| KR20150137118A (ko) | 2015-12-08 |
| GB201305940D0 (en) | 2013-05-15 |
| EP2981827A2 (en) | 2016-02-10 |
| CA2908527A1 (en) | 2014-10-09 |
| CN105283763B (zh) | 2018-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016010510A2 (pt) | método, arranjo e uso do mesmo | |
| BR112015025255A2 (pt) | métodos e arranjos para uso no mesmo | |
| BR112018073178A2 (pt) | método, matriz e uso dos mesmos | |
| BR112018009071A8 (pt) | método para preparar uma amostra, composição homogenizada, métodos para gerar dados, para tratar uma doença, de identificação de um marcador, para determinar o prognóstico de um câncer, para determinar um perfil fenotípico, para armazenar a composição homogenizada, para preparar uma amostra de tecido e preparar a composição homogenizada | |
| BR112014011818A2 (pt) | método para realizar ensaios de quantificação | |
| BR112014006432A2 (pt) | biomarcadores do câncer de pulmão e seus usos | |
| MX390772B (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
| BR112015017473A2 (pt) | método para detectar um agente patogênico em uma amostra, e, kit de análise de agente patogênico | |
| BR112016019836A2 (pt) | método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito | |
| BR112016018044A2 (pt) | teste de diagnóstico molecular para prever resposta às drogas antiangiogênicas e prognóstico de câncer | |
| AR095363A1 (es) | Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1 | |
| BR112015018434A2 (pt) | método, e, conjunto para medir uma vitamina d | |
| BRPI0805387A2 (pt) | aparelho para teste de furo de poço e métodos de utilização de radiação eletromagnética nuclear para determinar as propriedades fluidas | |
| BR112013003391A2 (pt) | biomarcadores de câncer pancreático e usos dos mesmos | |
| BRPI1012526B8 (pt) | uso de axl como um biomarcador para a detecção da ocorrência de transição epitélio-mesenquimal (tem), métodos para detecção da ocorrência de tem, para identificação de um agente capaz de inibir ou reverter tem e uso de um kit | |
| GB201207297D0 (en) | Analytical methods and arrays for use in the same | |
| BR112016013976A2 (pt) | método para determinar se um indivíduo é afetado por um câncer, método para discriminar entre câncer colorretal e pancreático dentre indivíduos que resultam ser positivos para o método, método para determinar o estágio de um câncer colorretal em um indivíduo afetado e uso de um kit de rt-pcr quantitativo para performar o método | |
| MX2019008911A (es) | Metodos, matrices y usos de estos. | |
| BR112017011026A2 (pt) | métodos analíticos e arranjos para uso nos mesmos | |
| BR112015019567A2 (pt) | marcadores associados com inibidores de wnt | |
| BRPI0419002A (pt) | método para detectar e para diferenciação entre adenoma colorretal e/ou carcinoma colorretal, método para monitoramento do curso de adenoma colorretal, uso de transtirretina como biomarcador, sistema de teste, arranjo compreendendo moléculas de detecção | |
| BR112015024780A2 (pt) | metodo para determinar radiosensibilidade | |
| BR112016008956A2 (pt) | Detecção de atividade de clivagem de uma enzima | |
| BR112016029562A2 (pt) | métodos para tratar, diagnosticar e prognosticar uma malignidade hematológica | |
| BR112017006315A2 (pt) | agente terapêutico, uso de um agente terapêutico, métodos in vitro para determinar se um sujeito com melanoma tem um risco maior de desenvolver metástase, de determinação de um regime de tratamento para um sujeito que sofre de melanoma, de tratamento de um sujeito que sofre de melanoma, ensaio in vitro para predizer o risco aumentado de metástase e kits |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2664 DE 25-01-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |